A phase III randomised, double blind, placebo controlled trial of carboplatin/etoposide with or without thalidomide in small cell lung cancer

Submission date	Recruitment status No longer recruiting	Prospectively registered			
02/07/2003		☐ Protocol			
Registration date	Overall study status	Statistical analysis plan			
02/07/2003	Completed	[X] Results			
Last Edited	Condition category	Individual participant data			
29/10/2021	Cancer				

Plain English summary of protocol

http://cancerhelp.cancerresearchuk.org/trials/a-trial-of-chemotherapy-with-or-without-thalidomide-in-small-cell-lung-cancer

Contact information

Type(s)

Scientific

Contact name

Dr Siow Ming Lee

Contact details

Middlesex/UCL Hospitals
Meyerstein Institute of Oncology
Mortimer Street
London
United Kingdom
W1T 3AA
+44(0)20 7380 9091
sm.lee@uclh.org

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00061919

Protocol serial number

Cancer Research UK Ref. C1438/A2932

Study information

Scientific Title

A phase III randomised, double blind, placebo controlled trial of carboplatin/etoposide with or without thalidomide in small cell lung cancer

Acronym

Study 12

Study objectives

Since tumour growth and metastasis are angiogenesis dependent, therapeutic strategies aimed at inhibiting angiogenesis are theoretically attractive. Thalidomide has anti-angiogenic and anti-cachexic effects which may complement the anti-tumour effect obtained from chemotherapy. Preliminary data from a recently completed phase II trial in SCLC appeared to show promising clinical activity when thalidomide was added to chemotherapy and as maintenance therapy. The combination was well tolerated without adding to the expected toxicities of the chemotherapy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration.

Study design

Randomised double blind placebo controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Small cell lung cancer

Interventions

Patients on both arms will receive carboplatin on day one and etoposide on day one, two and three on a three weekly regimen (six cycles).

All patients will be randomised to receive either thalidomide or placebo daily beginning on day one for up to 24 months.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Cisplatin and Etoposide (PE Chemotherapy) and thalidomide.

Primary outcome(s)

To determine if survival is affected by the addition of thalidomide in patients with SCLC treated with carboplatin/ etoposide.

Key secondary outcome(s))

To determine the effects of thalidomide on: time to disease progression, toxicity, response rate, quality of life and, in selected centres, biological markers.

Completion date

07/11/2005

Eligibility

Key inclusion criteria

- 1. Histologically or cytologically confirmed small cell lung cancer
- 2. Limited or extensive stage disease
- 3. Have had no prior chemotherapy or radiotherapy
- 4. Have no symptomatic brain metastases thought to require immediate radiotherapy
- 5. No evidence of significant medical condition or laboratory finding which, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial
- 6. Either sex, age over 18
- 7. Eastern Cooperative Oncology Group (ECOG) performance status zero to three
- 8. Estimated life expectancy of at least eight weeks
- 9. Renal function adequate for chemotherapy i.e. Ethylene Diamine Tetraacetic Acid (EDTA) clearance greater than 60 ml/min
- 10. Women of Child-Bearing Potential (WCBP) MUST have a negative serum or urine pregnancy test (minimal sensitivity 50 mIU/mL) performed by healthcare professional within 24 hours before starting study medication
- 11. WCBP must agree to practice complete abstinence from heterosexual intercourse or to use two methods of contraception (must include one highly effective barrier method [i.e. intrauterine device, hormonal birth control pills, injections or implants, tubal litigation, partners vasectomy) and one additional effective barrier method (i.e. latex or polyurethane condom, diaphragm, cervical cap) while on study medication and for four weeks after the last dose of study medication
- 12. WCBP who are sexually active in a heterosexual relationship must agree to have pregnancy tests every four weeks while on study medication and four weeks after the last dose of study medication
- 13. Male patients (including those who have had a vasectomy) must use barrier contraception (latex or polyurethane condoms) when engaging in heterosexual activity with WCBP while on study medication and four weeks after the last dose of study medication
- 14. Pregnant or lactating women or WCBP not using adequate contraception are excluded.
- 15. All WCBP who have had unprotected sexual intercourse within two weeks prior to study entry should not start study until the beginning of her next period or a negative pregnancy test 16. No history of prior malignant tumour, unless patient has been without evidence of disease for at least three years or the tumour was a non-melanoma tumour or early cervical cancer

Participant type(s)

Patient

Healthy volunteers allowed

Age group

Adult

Lower age limit

18 years

Sex

Total final enrolment

724

Key exclusion criteria

- 1. Pregnant or lactating women or WCBP not using adequate contraception
- 2. Prior treatment with chemotherapy or radiotherapy
- 3. Evidence of significant medical condition or laboratory finding which, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial
- 4. Prior history of thromboembolic event (including: Pulmonary Embolism [PE], Deep Vein Thrombus [DVT], Cerebro-Vascular Accident [CVA] / Transient Ischaemic Attack [TIA])
- 5. Symptomatic brain metastases thought to require immediate radiotherapy
- 6. History of prior malignant tumour, unless the patient has been without evidence of disease for at least three years or the tumour was a non-melanoma skin tumour or early cervical cancer

Date of first enrolment

01/04/2003

Date of final enrolment

07/11/2005

Locations

Countries of recruitment

United Kingdom

England

Study participating centre Middlesex/UCL Hospitals London United Kingdom W1T 3AA

Sponsor information

Organisation

Sponsor not defined - Record supplied by London Lung Cancer Group

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (CRUK) (UK) (ref. C1438/A2932)

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	05/08/2009		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Plain English results		09/07/2010	29/10/2021	No	Yes